Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases

J Urol. 1996 Dec;156(6):1931-3.


Purpose: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.

Materials and methods: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.

Results: All tumors were grade 3 or 4 transitional cell carcinoma. Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease. Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months. The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later.

Conclusions: Cyclophosphamide associated bladder tumor is an aggressive disease. However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Transitional Cell / chemically induced*
  • Carcinoma, Transitional Cell / surgery
  • Cyclophosphamide / adverse effects*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Urinary Bladder Neoplasms / chemically induced*
  • Urinary Bladder Neoplasms / surgery


  • Cyclophosphamide